Enzymotec Ltd. (NASDAQ:ENZY) – Investment analysts at Jefferies Group upped their Q3 2017 EPS estimates for Enzymotec in a research note issued on Thursday. Jefferies Group analyst L. Alexander now forecasts that the biotechnology company will post earnings per share of $0.04 for the quarter, up from their prior forecast of $0.02.

Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.15. The company had revenue of $13 million during the quarter, compared to the consensus estimate of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the business posted $0.04 EPS.

TRADEMARK VIOLATION NOTICE: “Jefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/21/jefferies-group-analysts-boost-earnings-estimates-for-enzymotec-ltd-enzy.html.

Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Enzymotec from a “hold” rating to a “sell” rating in a research report on Monday, May 22nd. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. One equities research analyst has rated the stock with a sell rating and three have given a hold rating to the company. Enzymotec presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Shares of Enzymotec (NASDAQ ENZY) opened at 10.55 on Monday. Enzymotec has a one year low of $5.20 and a one year high of $10.65. The company has a 50 day moving average price of $8.55 and a 200 day moving average price of $8.54. The company’s market cap is $242.11 million.

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after buying an additional 380 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its stake in Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock worth $247,000 after buying an additional 3,113 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 7,322 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Enzymotec during the second quarter worth approximately $2,350,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.